DIRS.INFO The most relevant business & tech news

Although insulin list prices are high in the U.S., drugmakers typically pay substantial rebates to private insurers and government programs, resulting in lower prices for most Americans with insurance. U.S.-listed Novo Nordisk shares rose as much as 1.7% to $142.95, while Denmark-listed shares closed marginally higher on Tuesday. Eli Lilly shares were down slightly. "I think it is a relatively natural consequence of what we have seen their competitor Eli Lilly do. Eli Lilly, Sanofi and Novo Nordisk make up 90% of the U.S. market for insulin.

☆ Novo Nordisk joins Lilly in plans to slash U.S. insulin prices
▼ + stars: | 2023-03-14 | by ( ) www.reuters.com time to read: +1 min

March 14 (Reuters) - Novo Nordisk (NOVOb.CO) said on Tuesday it would cut U.S. list prices for several insulin drugs by up to 75% next year, joining rival Eli Lilly as drugmakers come under pressure for high prices of the life-sustaining treatment. The moves follow President Joe Biden's Inflation Reduction Act last year that capped insulin prices for Medicare recipients at $35 per month, but that does not extend to patients without insurance. Novo will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%. The company also said it would reduce the list price of unbranded insulin products to match lowered price of respective branded insulin products. Eli Lilly and Co (LLY.N) said earlier this month that it would cut the list prices for its most commonly prescribed insulin products by 70% from the fourth quarter of this year.

☆ Here are Monday's biggest analyst calls: Apple ,Tesla, First Republic, Roku, Sunrun, JPMorgan Chase & more
▼ + stars: | 2023-03-13 | by ( Michael Bloom | ) www.cnbc.com time to read: +19 min

Baird upgrades Truist to outperform from neutral Baird said it sees an attractive risk/reward for the regional bank. "Regional bank risk/reward trade-off improving, and we would get more aggressive on the regional bank side, upgrading TFC to Outperform." Bank of America reiterates Alphabet as buy Bank of America said it's bullish on Alphabet's entry into AI. Bank of America reiterates Roku as buy Bank of America said it's standing by the stock in the wake of the Silicon Valley Bank collapse. "Regional bank risk/reward trade-off improving, and we would get more aggressive on the regional bank side, upgrading TFC to Outperform."

☆ Jim Cramer's top 10 things to watch in the stock market Monday: Banks slide, market tumbles
▼ + stars: | 2023-03-13 | by ( Jim Cramer | ) www.cnbc.com time to read: +3 min

Regulator action quells systemic risk from banks ( an outcome I pushed before Sunday evening's announcement) that had deposit risk and duration risk in the bond portfolios. Citi upgrades Charles Schwab (SCHW) to buy from neutral (hold) but lowers price target to $75 per share from $83. Boosts price target to $155 per share from $148. Hikes price target to $375 per share from $360. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Economists warn of costs if Medicare covers new obesity drugs
▼ + stars: | 2023-03-11 | by ( Nancy Lapid | ) www.reuters.com time to read: +3 min

March 11 (Reuters) - The cost of expanding U.S. Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday. Big-selling diabetes drugs have been repurposed as obesity treatments after demonstrating weight loss of more than 20% in clinical trials. While they are far more effective than older drugs, lifetime use might be required to keep lost weight off. But should the bipartisan The Treat and Reduce Obesity Act get reintroduced and passed by Congress, Medicare will be compelled to cover drugs for weight loss. The Medicare health program covers more than 60 million Americans, most over age 65.

☆ Here’s our fourth-quarter earnings report card for all the stocks in our portfolio
▼ + stars: | 2023-03-10 | by ( Zev Fima | ) www.cnbc.com time to read: +20 min

Fourth-quarter earnings season is in the rearview mirror and most Club stocks reported results ahead of, or in line with, analysts' forecasts. Moreover, excluding foreign exchange fluctuations, this marked the ninth quarter in a row of 20% or better annual earnings growth. Nvidia (NVDA) reported a very strong quarter and better-than-expected guidance for the current quarter . Eli Lilly 's (LLY) fourth-quarter results came up a bit short on revenue but delivered a strong bottom line. Despite missing on top-line expectations, Wells Fargo 's (WFC) earnings came in better-than-expected, as the bank realized the benefits of higher interest rates .

☆ Here are Thursday's biggest analyst calls: Apple, Tesla, Target, Goldman Sachs, Meta, FedEx & more
▼ + stars: | 2023-03-09 | by ( Michael Bloom | ) www.cnbc.com time to read: +12 min

Bank of America reiterates Goldman Sachs as buy Bank of America said the investment bank is "best-in-class." Bank of America reiterates Taiwan Semiconductor as buy Bank of America said the semiconductor company has "strong AI potential." Evercore ISI reiterates Meta as a top pick Evercore named Meta a top pick, noting it still likes the company's business model. " Evercore ISI reiterates Meta as a top pickEvercore named Meta a top pick, noting it still likes the company's business model. Oppenheimer reiterates Meta as outperformOppenheimer said it's standing by its outperform rating on Meta.

☆ Jim Cramer's top 10 things to watch in the stock market Thursday: Jobs, Fed, crypto
▼ + stars: | 2023-03-09 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Club holding Eli Lilly (LLY) says trial results show its older Alzheimer's drug failed to slow cognitive decline. Oppenheimer says Club holding Meta Platforms (META) has figured out how to give more data to advertisers, and that's driving shares higher. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

☆ Eli Lilly, Apple and Salesforce each made news on Thursday — our Club takes
▼ + stars: | 2023-03-09 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

A trio of Club stocks — Eli Lilly (LLY), Apple (AAPL) and Salesforce (CRM) — are in the news Thursday. The news: Eli Lilly is ending clinical development for one of its older Alzheimer's drugs — known as solanezumab — following another failed trial. Eli Lilly shares have struggled so far this year, falling more than 13%. In a note to clients, the firm said Eli Lilly "remains one of our favorite names" in the industry. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

☆ Top 10 things the Club is watching in the stock market Tuesday: Fed's Powell, Meta, obesity
▼ + stars: | 2023-03-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Meta Platforms ' (META) "year of efficiency" set to continue: Bloomberg is reporting job cuts in the thousands could happen as soon as this week. WW International (WW) is higher after announcing deal to acquire the anti-obesity-focused telehealth provider Sequence. (Jim Cramer's Charitable Trust is long META, LIN, CSCO, AMZN, LLY. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Jim Cramer's Investing Club meeting Monday: Fed and jobs, China reopening, Eli Lilly
▼ + stars: | 2023-03-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Fed and jobs report Stocks were trading higher Monday as investors look ahead to Federal Reserve commentary and new economic data later this week. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Top 10 things the Club is watching in the stock market Monday
▼ + stars: | 2023-03-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Morgan Stanley's Adam Jonas raises his price target on Ferrari (RACE) to $310 per share from $280. Pfizer (PFE) started with a neutral (hold) rating. Jefferies downgrades RH (RH), formerly known as Restoration Hardware, to hold, price target to $298 per share on concerns the luxury market is struggling to stabilize. Calls the chipmaker top cloud pick with a $275-per-share price target, ahead of multiple catalysts. General Electric (GE) coverage transferred at JPMorgan, which maintains neutral (hold) rating but increases price target to $88 per share.

☆ Jim Cramer's Investing Club meeting Friday: Costco, Eli Lilly, Apple
▼ + stars: | 2023-03-03 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Stick with Costco Watch Eli Lilly Own Apple 1. Morgan Stanley predicted the results could lead to a 5% to 10% upside for both Novo and Eli Lilly shares. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Top 10 things the Club is watching in the stock market Friday
▼ + stars: | 2023-03-03 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Club holding Costco (COST) was a little disappointing Thursday evening, with an earnings beat overshadowed by some softer February trends. Analysts outline five "underappreciated catalysts" that they think will drive a re-rating of the Club holding in the next twelve months. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

LONDON, March 2 (Reuters) - Drugmaker Viatris Inc (VTRS.O) warned on Thursday that it will stop selling some essential medicines in the UK that are already in short supply unless the British government makes changes to its voluntary medicines pricing agreement. If that level is exceeded, the government recoups the excess from suppliers of branded drugs. His colleague Viatris' Head of Europe Artur Cwiok named Germany and Portugal as countries where governments were weighing changes to drug pricing. If Viatris opted to leave that pricing scheme, it would have to pay a rate in the statutory scheme the government says will rise to 27.5%. Pharma companies AbbVie Inc (ABBV.N) and Eli Lilly and Co (LLY.N) withdrew from the pricing scheme in January.

Eli Lilly, along with Sanofi (SASY.PA) and Novo Nordisk (NOVOb.CO) make up 90% of the U.S. market for insulin. Biden, a Democrat, on Tuesday called on Congress and other manufacturers to lower the price of insulin as Lilly had done. The list price for Lispro, a cheaper version of its Humalog insulin, is currently $82.41 for 100 units/mL vials. List prices for drugs often differ from what patients actually pay, including after insurance and other assistance programs. Ricks said the company's insulin price cuts had been planned for some time and were accounted for in Eli Lilly's December financial forecast, which projected 2023 revenue of at least $30.3 billion.

☆ Here’s our Annual Meeting update on the 7 health care and bank stocks in the Club portfolio
▼ + stars: | 2023-03-01 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Here's an update on the health care and financial holdings in Jim Cramer's Charitable Trust, the portfolio we use at the CNBC Investing Club. At levels below $250 per share, Jim said Danaher is one of the most attractive stocks in the Club's portfolio. Its consumer-products unit will become a company known as Kenvue, while its faster-growing pharmaceutical and medical devices divisions will retain the J & J name. However, there is some litigation risk with J & J after a federal judge in January rejected its strategy concerning more than 38,000 talc lawsuits. Against that backdrop, we view J & J as a quality defensive name to own, especially given its annual dividend yield of around 3%.

☆ Jim Cramer's top 10 things to watch in the stock market Wednesday: China, stocks, retail
▼ + stars: | 2023-03-01 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

(See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Jim Cramer's Investing Club meeting Wednesday: China, Eli Lilly, P&G
▼ + stars: | 2023-03-01 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Stay bullish on China Stick with Eli Lilly Watch P & G 1. If investors continue to put their cash in Treasuries and yields rise, P & G stock could come under further pressure. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Biden says other companies will slash insulin prices after Eli Lilly move
▼ + stars: | 2023-03-01 | by ( Trevor Hunnicutt | ) www.reuters.com time to read: +1 min

BALTIMORE, March 1 (Reuters) - U.S. President Joe Biden said on Wednesday that other pharmaceutical companies will have to lower their insulin prices in the wake of Eli Lilly's decision to slash its prices for the popular diabetes treatment. Eli Lilly (LLY.N) said on Wednesday it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year. U.S. President Joe Biden discusses health care costs and access to affordable health care during an event in Virginia Beach, Virginia, U.S., February 28, 2023. REUTERS/Leah Millis"Guess what that means?," Biden told Democrats gathered in Baltimore for an annual retreat. Biden’s signature legislative achievement, the Inflation Reduction Act, has capped insulin prices for Medicare recipients at $35 per month but the law does not extend to patients with private insurance or without insurance from higher prices.

☆ Here are Wednesday's biggest analyst calls: Apple, Procter & Gamble, Tesla, Spotify, AbbVie & more
▼ + stars: | 2023-03-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Morgan Stanley upgrades Sarepta to overweight from equal weight Morgan Stanley said it's bullish on the company's gene therapy drug, SRP-9001. Morgan Stanley reiterates Rivian as overweight Morgan Stanley said it's standing by its overweight rating on the EV maker after its earnings report on Tuesday, but says it's now a show-me story. Morgan Stanley reiterates Eli Lilly as top pick Morgan Stanley said the stock is best-in-class and that it's bullish on its diabetes drug, Mounjaro. Morgan Stanley names JD.com a catalyst driven idea Morgan Stanley said it's bullish heading into the China e-commerce company's earnings on March 9. Morgan Stanley reiterates Microsoft as overweight Morgan Stanley said it's standing by shares of Microsoft.

Organizations: ~$

☆ Lilly to cut U.S. insulin prices by 70% from fourth quarter
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +2 min

March 1 (Reuters) - Eli Lilly and Co (LLY.N) will cut list prices by 70% for its most commonly prescribed forms of insulin, Humalog and Humulin, beginning from the fourth quarter of this year, the drugmaker said on Wednesday. Around 8.4 million of the 37 million people in the United States with diabetes use insulin, according to the American Diabetes Association. Eli Lilly, along with Sanofi (SASY.PA) and Novo Nordisk (NOVOb.CO) make up 90% of the U.S. market for insulin. Drugmakers had previously priced insulin at more than $275 a vial, representing a 1,200% increase in price over the past 20 years, according to the advocacy group Insulin Initiative. Reporting by Bhanvi Satija in Bengaluru; Additional reporting by Susan Heavey, Editing by Arun KoyyurOur Standards: The Thomson Reuters Trust Principles.

☆ Insulin cuts make drug prices a little less bazaar
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +2 min

If drug companies don’t play along, insurance companies will go elsewhere. The list price of Sanofi’s (SASY.PA) insulins rose 143% between 2012 and 2021, but the net price fell 54%. Amgen (AMGN.O) offered an autoimmune disease drug earlier this year with two prices. American politicians have been pressuring drug companies to lower prices, and President Joe Biden welcomed the move. In theory, lower list prices mean everyone pays less out of pocket at the pharmacy.

☆ Eli Lilly's diabetes drug back to shelf after two-month shortage
▼ + stars: | 2023-02-22 | by ( ) www.reuters.com time to read: +1 min

Feb 21 (Reuters) - Eli Lilly & Co (LLY.N) said on Tuesday all doses of its new diabetes drug Mounjaro were now available with wholesalers having inventory on hand after a two-month-long shortage. "Because Mounjaro is still a launch product with dynamic demand, some pharmacies may continue to experience intermittent delays from time to time," Eli Lilly told Reuters in an emailed statement. In December, the U.S. health regulator had added Mounjaro to its list of drugs facing shortages, highlighting Lilly's struggles to meet booming demand for the newly approved diabetes injection. Mounjaro was approved in the United States last May to help people with type 2 diabetes control their blood sugar levels. The company anticipates the drug, which has the common name tirzepatide, to get nod for obesity, an even bigger market, next year.

☆ Here's how Wall Street pros traded 13 Club stocks last quarter, including Salesforce and Disney
▼ + stars: | 2023-02-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

Big-name investors and hedge funds made moves in Club holdings Disney (DIS), Nvidia (NVDA) and TJX Companies (TJX) in the fourth quarter. Starboard's position stood at 3.03 million shares — valued at $401.22 million — at the end of the fourth quarter, according to the firm's 13F. Inclusive's 1.63 million shares were worth $216.77 million and ValueAct's 560,221 shares carried a market value of $74.28 million. CRM YTD mountain Salesforce (CRM) YTD performance In addition to Salesforce, a number of other Club holdings appeared in hedge funds' quarterly disclosures. Some of the activists swarming at Salesforce have positions in other Club holdings and made changes to them during the fourth quarter.

Search resuls for: "LLY"

25 mentions found